Symphogen A/S - Product Pipeline Review - 2016

  • ID: 4035467
  • Company Profile
  • 38 pages
  • Global Markets Direct
1 of 4
Symphogen A/S - Product Pipeline Review - 2016

Summary

‘Symphogen A/S - Product Pipeline Review - 2016’, provides an overview of the Symphogen A/S’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Symphogen A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

- The report provides a snapshot of the pipeline therapeutic landscape of Symphogen A/S
- The report provides overview of Symphogen A/S including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Symphogen A/S’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Symphogen A/S’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to Buy:

- Evaluate Symphogen A/S’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Symphogen A/S
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Symphogen A/S’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
Introduction

Symphogen A/S Snapshot

Symphogen A/S Overview

Key Facts

Symphogen A/S - Research and Development Overview

Key Therapeutic Areas

Symphogen A/S - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Symphogen A/S - Pipeline Products Glance

Symphogen A/S - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Symphogen A/S - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Symphogen A/S - Drug Profiles

futuximab + modotuximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies 1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit LAG-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit TIM-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sym-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYM-015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Symphogen A/S - Pipeline Analysis

Symphogen A/S - Pipeline Products by Target

Symphogen A/S - Pipeline Products by Route of Administration

Symphogen A/S - Pipeline Products by Molecule Type

Symphogen A/S - Pipeline Products by Mechanism of Action

Symphogen A/S - Dormant Projects

Symphogen A/S - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

rozrolimupab

Symphogen A/S - Company Statement

Symphogen A/S - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Symphogen A/S, Key Facts

Symphogen A/S - Pipeline by Indication, 2016

Symphogen A/S - Pipeline by Stage of Development, 2016

Symphogen A/S - Monotherapy Products in Pipeline, 2016

Symphogen A/S - Combination Treatment Modalities in Pipeline, 2016

Symphogen A/S - Phase II, 2016

Symphogen A/S - Phase I, 2016

Symphogen A/S - Preclinical, 2016

Symphogen A/S - Discovery, 2016

Symphogen A/S - Pipeline by Target, 2016

Symphogen A/S - Pipeline by Route of Administration, 2016

Symphogen A/S - Pipeline by Molecule Type, 2016

Symphogen A/S - Pipeline Products by Mechanism of Action, 2016

Symphogen A/S - Dormant Developmental Projects,2016

Symphogen A/S - Discontinued Pipeline Products, 2016

Symphogen A/S, Subsidiaries

List of Figures:

Symphogen A/S - Pipeline by Top 10 Indication, 2016

Symphogen A/S - Pipeline by Stage of Development, 2016

Symphogen A/S - Monotherapy Products in Pipeline, 2016

Symphogen A/S - Combination Treatment Modalities in Pipeline, 2016

Symphogen A/S - Pipeline by Target, 2016

Symphogen A/S - Pipeline by Route of Administration, 2016

Symphogen A/S - Pipeline by Molecule Type, 2016

Symphogen A/S - Pipeline Products by Mechanism of Action,
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll